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NeuroD1 regulation of migration accompanies the differential
sensitivity of neuroendocrine carcinomas to TrkB inhibition
JK Osborne1, JE Larsen2, JX Gonzales1, DS Shames2,4, M Sato2,5, II Wistuba3, L Girard1,2, JD Minna1,2 and MH Cobb1
The developmental transcription factor NeuroD1 is anomalously expressed in a subset of aggressive neuroendocrine tumors.
Previously, we demonstrated that TrkB and neural cell adhesion molecule (NCAM) are downstream targets of NeuroD1 that
contribute to the actions of neurogenic differentiation 1 (NeuroD1) in neuroendocrine lung. We found that several malignant
melanoma and prostate cell lines express NeuroD1 and TrkB. Inhibition of TrkB activity decreased invasion in several
neuroendocrine pigmented melanoma but not in prostate cell lines. We also found that loss of the tumor suppressor p53 increased
NeuroD1 expression in normal human bronchial epithelial cells and cancer cells with neuroendocrine features. Although we found
that a major mechanism of action of NeuroD1 is by the regulation of TrkB, effective targeting of TrkB to inhibit invasion may
depend on the cell of origin. These ﬁndings suggest that NeuroD1 is a lineage-dependent oncogene acting through its downstream
target, TrkB, across multiple cancer types, which may provide new insights into the pathogenesis of neuroendocrine cancers.
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INTRODUCTION
Aberrant expression of basic helix loop helix transcription factors
such as neurogenic differentiation 1 (NeuroD1) and achaete-scute
homolog1 has been observed in aggressive small cell lung cancer
(SCLC), neural and neuroendocrine lung carcinomas.1–4 Although
the developmental roles of these basic helix loop helix proteins
are well established, their possible causative roles in the
pathogenesis of neuroendocrine carcinomas are less
understood. Neuroendocrine tumors can initiate from almost
any organ system. Although described based on organ of origin,
this feature is not limiting, as many of these tumors share
pathological characteristics such as expression of the
neuroendocrine markers synaptophysin and chromogranin A,
and the neural cell adhesion molecule (NCAM, also known as
CD56).5–7 Neuroendocrine tumors are thought to originate from
neuroendocrine cells, or to undergo an epithelial to
neuroendocrine differentiation that leads to more aggressive
carcinomas, as observed in melanoma and cancers of the
gastrointestinal tract and prostate.2,8–14 To investigate the role
of NeuroD1 in tumorigenesis, we examined several tissue types.
We report that several pigmented melanoma cell lines express
high amounts of NeuroD1 and conﬁrmed previous ﬁndings in
prostate cell lines.2 We ﬁnd that regulation of TrkB is conserved
across multiple tissue types. Additionally, downregulation of both
NeuroD1 and TrkB prevented viability and migration of several
carcinomas; however, inhibition of TrkB activity only had an effect
in cell lines with the neuroendocrine feature as deﬁned by the
presence of the neuroendocrine markers synaptophysin and
NCAM. We also determined that loss of p53 is permissive for
increased expression of NeuroD1, possibly in a lineage-dependent
manner.
RESULTS
NeuroD1 is highly expressed in aggressive neuroendocrine
cancers
To investigate the clinical signiﬁcance, expression of NeuroD1 was
examined in a data set including more than 5400 patient samples
taken from tumor and normal tissues. Elevated NeuroD1 expres-
sion was observed in several malignant tumors, including those
from the neuroendocrine tissues, pancreas, brain, and lung, all of
which were SCLC (Figure 1a, Supplementary Tables S1 and S2).
Previously, we have demonstrated that NeuroD1 promotes tumor
cell survival and metastasis in aggressive neuroendocrine lung
tumors through regulation of the tyrosine kinase receptor, TrkB.15
To complement studies in the lung, we examined the role of
NeuroD1 in cell lines from non-neural or non-neuroendocrine cells
that undergo neuroendocrine differentiation.2,16 The conse-
quences of NeuroD1 expression have not been investigated in
malignant melanoma, even though it has been suggested to
induce neuroendocrine differentiation in conjunction with
oncogenic B-RAFV600E under certain circumstances.17,18 NeuroD1
was observed in prostate cancer; however, its expression in several
of the commonly used prostate cancer cell lines was only noted
upon in vitro differentiation with cAMP.2 We observed that
NeuroD1, TrkB, and NCAM expression was greater in melanoma
cell lines that were reported to have higher pigmentation and
metastatic potential19,20 (Figure 1b and Supplementary Figure 1a).
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The tendency of increasing expression of the three factors with
increasing pigmentation appeared to be independent of the
mutational status of B-RAF, as all cell lines with the exception of
WM3211 have V600 mutations.21–23 As in SCLC, increased
expression of the neuroendocrine marker synaptophysin was
also detected in melanomas with high NeuroD1 (Figures 1b and c).
NeuroD1 was also expressed in undifferentiated malignant
prostate cell lines; however, neither of the neuroendocrine
markers, synaptophysin or NCAM, were detected (Figure 1d).
Loss of p53 increased NeuroD1 expression
We next sought to investigate speciﬁc onco-genotypes possibly
responsible for expression of NeuroD1. To do this we utilized
human bronchial epithelial cell (HBEC) lines that were assigned a
number to distinguish lines from different individuals and
immortalized them by overexpression of cyclin-dependent kinase
4 and human telomerase reverse transcriptase (for example,
HBEC3KT).24 The immortalized HBEC3KT cell line was sequentially
transformed by knockdown of the tumor suppressor p53 and
expression of K-RasV12 (HBEC3KTRL53)
25 (also, Sato et al26).
NeuroD1 expression was increased in HBEC3KT53 cells, a non-
tumorigenic derivative with stable knockdown of p53 (Figure 2a).
Additionally, isogenic derivatives of HBEC3KT that were trans-
formed from normal to tumorigenic cells followed by clonal
selection (HBEC3KTRL53-Clone 5, hereafter called Clone 5)
exhibited spontaneous expression of NeuroD1 (Figure 2a). Sus-
tained inactivation of p53 is suggested to enhance tumorigenesis
at multiple stages, including initiation and progression.13,24,27–30
To test a possible relationship between p53 and NeuroD1, we re-
expressed p53 in the tumorigenic cell line Clone 5 and found a
substantial decrease in NeuroD1 mRNA (Figure 2b). Next, we
utilized a luciferase construct driven by the mouse Neurod1
proximal promoter to determine if p53 expression affected
promoter activity. A 100-fold increase in Neurod1 promoter
activity was observed in immortalized HBEC3KT53 compared with
the parental HBEC3KT (Supplementary Figure 1A). Furthermore,
re-expression of p53 in HBEC3KT53 and Clone 5 led to a dramatic
reduction in Neurod1 promoter reporter activity (Figure 2c). From
this HBEC model we concluded that loss of p53 induced NeuroD1
expression, suggesting that p53 may regulate NeuroD1 early in
the pathogenesis of neuroendocrine lung cancer.
To evaluate p53 as a determinant of NeuroD1 expression in
neuroendocrine cancers, we analyzed its expression in lung,
prostate and melanoma cells with loss of (H358, PC3, and YUMAC)
or mutation in (H1155, M14, SK-MEL-2 and SK-MEL28) p5331,32
(Figure 2d). Overexpression of p53 only suppressed NeuroD1 in
cells that also had neuroendocrine features, not in the three non-
neuroendocrine cell lines (Figure 2e). Together, these results
suggest a role for loss of p53 being permissive for NeuroD1
expression, not only in neuroendocrine lung cancers but also, as
recently suggested, in melanoma pathogenesis.33
NeuroD1 and TrkB regulates viability and migration of prostate
and melanoma cell lines
Previously, we have demonstrated that knockdown of NeuroD1
and its downstream target TrkB led to a decrease in survival and
migration of neuroendocrine lung cancers.15 We observed that
loss of NeuroD1 resulted in loss of TrkB in all lines tested,
indicating a conserved connection between NeuroD1 and TrkB
across multiple cancer types (Supplementary Figure 2a). NeuroD1
has the ability to regulate the promoter of TrkB in neural and
neuroendocrine lung cancers.15,34 We sought to investigate if
NeuroD1 bound the promoter of TrkB in the melanoma and the
prostate cell lines using chromatin immunoprecipitation.
12
10
8
6
4
Black -Normal Red -Cancer
N
eu
ro
D
1
e
xp
re
ss
io
n 
(lo
g2
)
Melanoma
NeuroD1
TrkB
Synaptophysin
Tubulin 
NCAM
Pigment
Prostate
NeuroD1
TrkB
Synaptophysin
NCAM
GAPDH
Lung
Synaptophysin
Tubulin
Figure 1. NeuroD1 is expressed in aggressive neuroendocrine lung cancers. (a) Expression of NeuroD1 mRNA compared across diverse normal
(N¼ 3879; black dots) and malignant tissues (N¼ 1605; red dots) using the Affymetrix HGU133 Plus v2 GeneChip. (b, d) Melanoma and
prostate cancer cell lines were lysed, and 25 mg total protein was loaded and then immunoblotted for NeuroD1, TrkB, NCAM, synaptophysin
and tubulin or GAPDH (as loading controls). Melanoma cell lines were loaded by increasing pigmentation. (c) Lung cancer cell lines were lysed
and 25 mg of total protein was immunoblotted for synaptophysin and tubulin (as loading controls).
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Endogenous NeuroD1 was bound to the TrkB promoter in all cell
lines; the enrichment of NeuroD1 on the TrkB promoter was
greater than 100-fold in both YUMAC and Mnt1 cell lines at the
more distal site and closer to 10-fold or less in the other cell lines
(Supplementary Figure 3).
Next we tested the possible functions of NeuroD1 and TrkB in
the prostate and melanoma cell lines. Loss of NeuroD1 in prostate
and melanoma cell lines signiﬁcantly reduced viability and
migration (Figures 3a and b). Depletion of TrkB signiﬁcantly
decreased the viability and migration of all the melanoma cell
lines (Figures 3c and d and Supplementary Figure 4), but prostate
cancer cell lines differed, as loss of TrkB decreased migration but
not viability (Figures 3c and d and Supplementary Figure 4).
Additionally, knockdown of either NeuroD1 or TrkB led to a
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Figure 2. Loss of p53 is permissive for expression of NeuroD1. (a) NeuroD1, p53 and GAPDH (loading control) were immunoblotted in lysates
of HBEC3KT, HBEC3KT53 and Clone 5. (b) qRT–PCR analysis of NeuroD1 in Clone 5 cells transfected as indicated. A representative p53
immunoblot is shown from one of three independent experiments. (c) HBEC3KT53 and Clone 5 were transfected with pGL3-NeuroD1-
luciferase with and without p53. p53 was immunoblotted and luciferase activity was measured; one of six experiments shown. (d) Melanoma,
prostate and lung cancer cell lines were lysed; 50mg total protein was immunoblotted for p53, NeuroD1 and GAPDH (as loading control). The
dashed line indicates discontinuity in gel. The asterisk represents a loss-of-function mutation in p53.43 (e) Cell lines with loss of or mutation in
p53 were transfected with control vector or vector encoding p53. Cells were lysed and immunoblotted for p53. Overexpression was quantified
using Odyssey software.
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signiﬁcant decrease in proliferation as measured by BrdU
incorporation in Mnt1 and YUMAC, melanoma cells, and the
LnCAP and Du145, prostate cells (Figure 3e and Supplementary
Figure 2b). Taken together, these results indicate that NeuroD1
and TrkB regulate proliferation, viability and migration in several
melanoma and prostate cancer cell lines.
TrkB regulates cell survival and migration in melanoma but not
prostate cancer cell lines
We next investigated if chemical inhibition of TrkB would
phenocopy the loss of NeuroD1 in melanoma and prostate cancer
cells. We then treated the melanoma and prostate cell lines with
the pan-Trk inhibitor lestaurtinib to ascertain if chemical inhibition
would mimic loss of TrkB. The melanoma cell lines exhibited a
phenotype similar to the neuroendocrine lung cancer cell lines in
that treatment with nanomolar concentrations of lestaurtinib
reduced cell viability (Figure 4a). The prostate cell lines, however,
were resistant to the inhibitor below micromolar concentrations,
suggesting a divergence in the actions of TrkB in non-
neuroendocrine cells (Figure 4b). The capacity of melanoma cells
to invade through matrigel was inhibited by lestaurtinib
(Figure 4c), whereas the prostate cell lines were resistant
(Figure 4d). Treatment with lestaurtinib decreased active TrkB in
the melanoma cell line similar to its effect on the SCLC cell line,
H82 (Figure 4e). Lestaurtinib had no effect on phosphorylated Trk
in the LnCAP or PC3 prostate cell lines, apparently explaining the
lack of an effect on migration or viability (Figure 4e). Lestaurtinib
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Figure 3. NeuroD1 and TrkB regulates viability and migration of prostate and melanoma. (a) NeuroD1 was transiently knocked down in
melanoma or prostate in 96-well formats. Cells were assayed for viability using Cell-Titer Blue. Graph represents fold mean±s.d. of three
independent experiments in triplicate (**Po0.005, *Po0.05; one-way ANOVA). (b) NeuroD1 was transiently knocked down in prostate and
melanoma cell lines and cells were subjected to transwell migration assay. (c) TrkB was transiently knocked down in melanoma or prostate in
96-well formats. Cells were assayed for viability using Cell-Titer Blue. Graph represents fold mean±s.d. of three independent experiments in
duplicate (**Po0.005, *Po0.05; one-way ANOVA). (d) TrkB was transiently knocked down in melanoma or prostate and subjected to transwell
migration assay. Graph represents fold mean±s.d. of three independent experiments in triplicate (**Po0.005, *Po0.05; one-way ANOVA).
(e) NeuroD1 and TrkB were transiently knocked down in melanoma or prostate cells in 96-well format for 3 days. Cells were then assayed for
BrdU incorporation.
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did decrease viability and migration of LnCAP; however, these
effects were not through a decrease in phosphorylated TrkB and
may be due to another target of the drug (Figures 4b and d). We
hypothesized that even if NeuroD1 was highly expressed, its
mechanisms of action through TrkB may be dependent on the cell
of origin. Neuroendocrine differentiation, deﬁned by the presence
of synaptophysin, was observed in the melanoma and neuroen-
docrine lung cancer cell lines, but not in the prostate cell lines
(Figures 1b and d). We suggest that NeuroD1 and TrkB regulate
migration in neuroendocrine and non-neuroendocrine cancer
cells, but the efﬁcacy of targeting TrkB may depend on the cell of
origin.
DISCUSSION
Neurogenic basic helix loop helix transcription factors, including
NeuroD1, are found to have increased expression in neural and
neuroendocrine tumors. Whether their expression was causative
or solely a consequence of disease had not been deter-
mined.1,4,9,14,35 Recently, NeuroD1 was implicated in the
tumorigenesis of neuroblastoma.36 Our data reveal a novel
function for NeuroD1 in the induction and coordination of
signal transduction pathways that regulate survival and
migration of non-neural/neuroendocrine cancers. We now
demonstrate that NeuroD1 promotes survival and migration in
neuroendocrine lung and other carcinomas at least in part
through TrkB.
HBEC models provided a useful system to explore NeuroD1
function. Our studies suggest that p53 negatively regulates
NeuroD1 expression not only in HBEC but also in carcinomas
with neuroendocrine features. Loss of p53 did not unilaterally
result in an increase in NeuroD1 expression, as observed in the
non-neuroendocrine lung and prostate cell lines. Unlike cells of
the prostate, melanocytes derive from neural crest cells migrating
from the dorsal neural tube to the dermis, making them
neuroectoderm in origin.37,38 Furthermore, p53 is not only a
potent tumor suppressor, but also suppresses self-renewal of adult
neural stem cells.39 NeuroD1 has also been shown to enhance
proliferation of committed neuronal progenitor cells.40 Perhaps
p53-mediated inhibition of NeuroD1 in neuroendocrine cells
present in non-neural tissues may in some respects parallel its
effect on determination of neuronal cell fate.
Surprisingly, inhibition of TrkB kinase activity is apparently not
equally signiﬁcant in the three cancer types examined: lung,
melanoma, and prostate. TrkB activity is important for neither
migration nor viability in prostate cancer cell lines. We speculate
0
50
100
150
Du145
Vehicle
Lestautinib
%
 c
el
ls
 in
va
di
ng
 m
at
rig
el
%
 c
el
ls
 in
va
di
ng
 m
at
rig
el
%
 v
ia
bl
e 
ce
lls
%
 v
ia
bl
e 
ce
lls
MNT1 YUMAC
LnCAP
Lestaurtinib
PC3 Du145
pTrk
TrkB
pTrk
TrkB
0
20
40
60
80
100
120
H82
NT
Lestaurtinib
pT
rk
/T
rk
B
Lestaurtinib
0
25
50
75
100
125 H82
H1155 
UACC257
YUMAC
MNT1
0
25
50
75
100
125 H82
H1155 
LnCAP
PC3
Du145
Lestaurtinib, uM
*
Lestaurtinib, uM
0
50
100
150
YUMAC
Vehicle
Lestautinib
GAPDH
GAPDH
UACC257
2020.20.02Control 2020.20.02Control
* *
MNT1UACC257 LnCAPPC3
+-+-+-
+-+-+- PC3LnCAPDu145MNT1YUMAC
Figure 4. TrkB activity regulates cell survival and migration in melanoma but not prostate cancer cell lines. (a, b) Viability of neuroendocrine
lung, prostate and melanoma cells was measured after a treatment with 0.02, 0.2, 2, 20 mM lestaurtinib for 96 h, using Cell-Titer Blue.
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this may be because of the following reasons: (1) prostate cancer
cells do not express the neuroendocrine marker synaptophysin in
contrast to melanoma and SCLC, which possibly links them in a
neuroendocrine pathology; (2) prostate, unlike melanoma or SCLC,
expresses smaller forms of TrkB, possibly TrkB splice variants
thought to be inhibitory due to lack of the kinase domain;41 (3) the
effects of NeuroD1 on prostate viability and migration may be
mediated by pathways independent of TrkB. Ultimately, additional
characteristics must be identiﬁed to distinguish between TrkB
inhibitor-sensitive and insensitive tumor types.
The ﬁndings here suggest that NeuroD1 acts as a lineage-
speciﬁc regulator of survival and migration in cells with
neuroendocrine features mainly through TrkB, which may be
potentiated by loss of p53 (Figure 5). The discovery of down-
stream targets of NeuroD1 in non-neuroendocrine/non-neural
tumors is ongoing. The actions of the NeuroD1/TrkB axis may
differ outside of cancers with neuroendocrine features. The
development of drugs that act as inhibitors of transcription
factors has proven extremely difﬁcult. Cell surface proteins offer
greater opportunities for therapeutic intervention. In particular,
TrkB, a receptor and enzyme, has gained attention as a potential
target of drug development for neuronal and non-neuronal
metastatic carcinomas. NeuroD1-expressing neuroendocrine car-
cinomas should now also be considered for sensitivity to TrkB
inhibitors.
MATERIALS AND METHODS
Reagents, antibodies, immunoblotting
Immunoblot analyses were done as previously described using equal
amounts of protein from each sample.42 The following antibodies were
used for blotting, immunoprecipitation and chromatin immunoprecipita-
tion: goat NeuroD1 (N-19), rabbit pan-phospho-Trk (E-6), synaptophysin
(H-8), p53 (DO-1), GAPDH (FL-335) (Santa Cruz, Dallas, TX, USA); rabbit TrkB
(Chemicon/Millipore Billerica, MA, USA), mouse CD56/NCAM (Cell
Signaling, Danvers, MA, USA), a-tubulin hybridoma was purchased from
the Hybridoma Bank Studies at the University of Iowa. Lestaurtinib was
purchased from LC Labs, Woburn, MA, USA, and BDNF from R&D Systems
(Minneapolis, MN, USA). Band intensities were quantiﬁed using LICOR
Odyssey Infrared Imaging System (Linclon, NE, USA).
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as previously described.42
Twenty-ﬁve nanograms of total DNA was used for the quantitative RT-PCR
reactions. TrkB primers were as described previously.34
Quantitative real-time PCR
Total RNA from the xenograft tumors and cell lines was isolated with TRI
Reagent (Sigma-Aldrich, St Louis, MO, USA). RNA from tumor samples was
from MD Anderson Cancer Center (Houston, TX, USA). complementary
DNA was synthesized using iSCRIPT cDNA Synthesis Kit (Bio-Rad,
Laboratories, Hercules, CA, USA). RNAs for mouse and human NeuroD1,
TrkB, NCAM and 18s ribosomal RNA were quantiﬁed by RT-PCR with iTaq
(Bio-Rad) master mix using TaqMan probes (Applied Biosystems, Life
Technologies/Invitrogen, Grand Island, NY, USA) on an ABI 7500
thermocycler. Relative transcript levels were normalized to 18s rRNA.
Transcript amounts in knockdown cells were plotted as fold change
relative to control. Data were analyzed using ABI 7500 system software
(Life Technologies/Invitrogen).
Cell viability and proliferation assay
Cells were plated at a density of 105/well and reverse transfected with
small interfering RNA for 3 days. Viability after knockdown or drug was
assayed using Cell-Titer Blue Reagent according to the manufacturer’s
protocol by measuring ﬂuorescence as readout. Proliferation was
measured by incorporation of BrdU in cells for 24 h following reverse
transfection with indicated small interfering RNA for 3 days. Incorporation
was measured using the Cell Signaling Assay Kit #6813S.
Cell culture
SCLC and non-small-cell lung carcinoma lines were obtained from the
Hamon Cancer Center Collection (UT Southwestern). SCLC, non-small cell
lung cancers with neuroendocrine differentiation, HBEC3KTRL53-Clone 5
(Sato et al., submitted) and prostate cell lines were cultured in RPMI 1640
medium with 10% fetal bovine serum. Melanoma cell lines were cultured
in DMEM with 10% fetal bovine serum. Immortalized HBECs and RWPE
(normal immortalized prostate cells) (except HBEC3KTRL53-Clone 5)25 were
cultured in KSFM (Life Technologies/Invitrogen) with 5 ng/ml epidermal
growth factor and 50mg/ml bovine pituitary extract. The lung cancer cell
lines were DNA ﬁngerprinted using the PowerPlex 1.2 kit (Promega,
Madison, WI, USA) and conﬁrmed to be the same as the DNA ﬁngerprint
library maintained either by ATCC or by the Hamon Cancer Center. The
lines were also tested to be free of mycoplasma by e-Myco kit (Boca
Scientiﬁc, Boca Raton, FL, USA).
Migration assays
For migration assays, cells were seeded 48 h following knockdown of
NeuroD1 or TrkB. Transwell migration was assayed in Transwell permeable
supports (Corning #3422, Corning, NY, USA). Cells were seeded in the top
chamber in RPMI with 1% fetal bovine serum and allowed to migrate along
a concentration gradient through a polycarbonate membrane with 8 mm
pores to the bottom chamber containing medium with 10% fetal bovine
serum. After 24 h cells were ﬁxed, stained (with hematoxylin and eosin
stain), and counted. For invasion assays 1.5 105 cells were embedded in
growth factor reduced matrigel in the presence or absence of 100 nM
lestaurtinib in transwell permeable supports. Cells were allowed to migrate
for 48 h across membranes with a gradient of 10% serum in the bottom
chamber.
Microarray analysis
Five micrograms of total RNA was labeled and hybridized to Affymetrix
GeneChips HG-U133A and B according to the manufacturer’s protocol
(http://www.affymetrix.com) while 0.5micrograms of total RNA was used
for Illumina BeadChip HumanWG-6 V3 (http://www.illumina.com). These
data are available in GEO (accession no. GSE4824 and GSE32036). Array
data were pre-processed with MAS5 (Affymetrix algorithm for probe
summarization) or MBCB (Illumina algorithm for background subtraction
(Ding et al, NAR 36 (10), 2008)), quantile-normalized and log-transformed
Microarray expression data of NeuroD1 mRNA were also compared
across diverse benign (N¼ 3879; black dots) and malignant tissues
(N¼ 1605; red dots) using the Affymetrix HGU133 Plus v2 GeneChip.
These data were obtained from Gene Logic, Inc. (Gaithersburg, MD, USA).
The analysis shown is for probe set ID 206282_at. The microarray data were
normalized using the RMA method.
Plasmids, primers, and luciferase assays
Oligonucleotides used were the following: NeuroD1-1 sense 50-CGAAUUU
GGUGUGGCUGUA-30 , antisense 50-UACAGCCACACCAAAUUCG-30 (QIAGEN,
Valencia, CA, USA); NeuroD1-AB sense 50-GGAUCAAUCUUCUCAGGCA-30 ,
antisense 50-UGCCUGAGAAGAUUGAUCC-30 (AMBION, Life Technologies/
Invitrogen); NTRK2–5 sense 50-GACGAGUUUGUCUAGGAAA-30 , antisense
50-UUUCCUAGACAAACUCGUC-30 (QIAGEN). For p53 experiments, cells
were transfected with pCMV5, SV40- internal control, pcDNA.1-p53 or
pGL3-NeuroD1 constructs using Fugene HD. Luciferase assays used the
Promega dual luciferase kit according to the manufacturer’s protocol.
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Figure 5. Working model. Model of NeuroD1 induction and
mechanism of action in neuroendocrine and non-neuroendocrine
cancers.
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Statistical analyses
Student’s t test, one-way analysis of variance (ANOVA), Pearson’s test and
linear regression were used to determine statistical signiﬁcance. Statistical
signiﬁcance for all tests was assessed by calculating the P values and was
deﬁned as o0.05.
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